| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 新型腔肠素底物及其使用方法 | CN201180063659.6 | 2011-11-02 | CN103443121A | 2013-12-11 | B·宾科夫斯基; L·P·昂塞尔; M·哈尔; M·B·罗贝斯; M·R·斯莱特; K·V·伍德; M·G·伍德 |
| 一种编码修饰的荧光素酶多肽和底物的分离的多核苷酸。OgLuc变体多肽与SEQ ID NO:1具有至少60%氨基酸序列同一性且在对应于SEQ ID NO:1中的氨基酸的位置处具有至少一个氨基酸置换。OgLuc变体多肽相对于野生型刺虾属荧光素酶的对应的多肽具有增强的发光、增强的信号稳定性和增强的蛋白质稳定性中的至少一项。 | ||||||
| 2 | 官能团与蛋白质及其底物的共价束缚 | CN200580032551.5 | 2005-07-29 | CN101115995A | 2008-01-30 | A·达津斯; L·P·恩塞尔; T·约翰逊; D·克劳伯特; G·V·洛斯; M·麦杜加尔; K·V·伍德; M·G·伍德; C·齐姆普里希 |
| 本发明提供任选地融合至目标蛋白的突变水解酶。所述突变水解酶能够与对应非突变(野生型)水解酶的底物形成相比于所述野生型水解酶和所述底物之间所形成的键更为稳定的键，所述突变水解酶相比于野生型水解酶具有至少两个氨基酸置换。本发明还提供含一个或多个官能团的水解酶底物，以及使用所述突变水解酶和本发明底物的方法。本发明还提供能够与底物形成稳定键的融合蛋白和表达所述融合蛋白的细胞。 | ||||||
| 3 | 新型腔肠素底物及其使用方法 | CN201180063659.6 | 2011-11-02 | CN103443121B | 2016-04-20 | B·宾科夫斯基; L·P·昂塞尔; M·哈尔; M·B·罗贝斯; M·R·斯莱特; K·V·伍德; M·G·伍德 |
| 一种编码修饰的荧光素酶多肽和底物的分离的多核苷酸。OgLuc变体多肽与SEQ ID NO:1具有至少60%氨基酸序列同一性且在对应于SEQ ID NO:1中的氨基酸的位置处具有至少一个氨基酸置换。OgLuc变体多肽相对于野生型刺虾属荧光素酶的对应的多肽具有增强的发光、增强的信号稳定性和增强的蛋白质稳定性中的至少一项。 | ||||||
| 4 | 一种通过分子影像学方法动态监测Stat3表达水平的细胞系 | CN201611154240.2 | 2016-12-14 | CN106591238A | 2017-04-26 | 王丹; 李宗金; 刘娜 |
| 本发明涉及构建一种通过分子影像学的方法动态监测Stat3表达水平的细胞系。该细胞系是将一种能指征Stat3表达水平的荧光素酶报告基因质粒通过慢病毒包装的方式转染到小鼠胚胎干细胞中，从而获得稳定转染了该报告基因的细胞系；在LIF激活Stat3并使Stat3发生磷酸化的前提下，p‑Stat3能入核与质粒上的p‑Stat3识别序列结合并进而启动下游荧光素酶基因Renilla的表达，在加入底物腔肠素后，Renilla利用细胞内的ATP氧化分解底物，并释放一个光子，释放的光子数与Stat3的激活水平成正比，因而利用该细胞系可以实现连续、动态地的监测Stat3的激活水平；因为成像底物能被荧光素酶氧化分解，对于细胞活性并无侵入性，而且可以在不同的时间点进行连续的成像监测Stat3激活的动态过程，这也是本细胞系优于传统实验方法的一大创新之处。 | ||||||
| 5 | 新型腔肠素底物及其使用方法 | CN201180062485.1 | 2011-11-02 | CN103370319B | 2016-08-24 | D.H.克劳伯特; P.梅森黑默; J.安奇 |
| 一种编码修饰的荧光素酶多肽的分离的多核苷酸和新型的基于腔肠素的底物。OgLuc变体多肽与SEQ ID NO：1具有至少60％氨基酸序列同一性且在对应于SEQ ID NO：1中的氨基酸的位置处具有至少一个氨基酸置换。OgLuc变体多肽相对于野生型刺虾属荧光素酶的对应的多肽具有增强的发光、增强的信号稳定性和增强的蛋白质稳定性中的至少一项。 | ||||||
| 6 | 新型腔肠素底物及其使用方法 | CN201180062485.1 | 2011-11-02 | CN103370319A | 2013-10-23 | D.H.克劳伯特; P.梅森黑默; J.安奇 |
| 一种编码修饰的荧光素酶多肽的分离的多核苷酸和新型的基于腔肠素的底物。OgLuc变体多肽与SEQ ID NO：1具有至少60％氨基酸序列同一性且在对应于SEQ ID NO：1中的氨基酸的位置处具有至少一个氨基酸置换。OgLuc变体多肽相对于野生型刺虾属荧光素酶的对应的多肽具有增强的发光、增强的信号稳定性和增强的蛋白质稳定性中的至少一项。 | ||||||
| 7 | 아포에쿼린-함유 조성물을 기반으로 하는 다발성 경화증의 증상을 완화시키는 방법 | KR1020157010986 | 2013-09-27 | KR1020150060954A | 2015-06-03 | 언더우드,마크,와이. |
| 아포에쿼린의투여에의해서다발성경화증과관련된증상을완화시키는방법이본 발명에의해서제공된다. 그러한증상은, 예를들어, 수면질, 에너지질, 감정질, 기억질 또는통증을포함한다. | ||||||
| 8 | 오플로포러스-유래된 루시퍼라아제, 신규 코엘렌테라진 기질, 및 사용 방법 | KR1020137014102 | 2011-11-02 | KR1020130084312A | 2013-07-24 | 빈코브스키브록; 엔셀랜스피.; 홀메리; 로버스매튜비.; 슬레이터마이클알.; 우드키스브이.; 우드모니카쥐.; 클로베르트디에터; 마이젠하이머폰초; 운치제임스; 밸리마이클피. |
| 변형된루시퍼라아제폴리펩타이드를인코딩하는단리된폴리뉴클레오타이드및 기질. OgLuc 변이체폴리펩타이드는서열번호: 1에대해적어도 60% 아미노산서열동일성및 서열번호: 1에서의아미노산에상응하는위치에서적어도하나의아미노산치환을갖는다. OgLuc 변이체폴리펩타이드는야생형루시퍼라아제의상응하는폴리펩타이드에관해증대된발광, 증대된신호안정성, 및증대된단백질안정성중 적어도하나를갖는다. | ||||||
| 9 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | US14160282 | 2014-01-21 | US09951373B2 | 2018-04-24 | Brock Binkowski; Lance P. Encell; Mary Hall; Matthew B. Robers; Michael R. Slater; Keith V. Wood; Monika G. Wood |
| An isolated polynucleotide encoding a modified luciferase polypeptide and substrates. The OgLuc variant polypeptide has at least 60% amino acid sequence identity to SEQ ID NO: 1 and at least one amino acid substitution at a position corresponding to an amino acid in SEQ ID NO: 1. The OgLuc variant polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the corresponding polypeptide of the wild-type Oplophorus luciferase. | ||||||
| 10 | REVERSIBLE IMMOBILIZATION AND/OR CONTROLLED RELASE OF NUCLEIC ACID CONTAINING NANOPARTICLES BY (BIODEGRADABLE) POLYMER COATINGS | US15450233 | 2017-03-06 | US20170239372A1 | 2017-08-24 | Patrick BAUMHOF; Hans-Peter WENDEL; Andrea NOLTE; Tobias WALKER |
| The present invention relates to nanoparticles comprising nucleic acids coated with a (biodegradable) polymer for reversible immobilization and/or controlled release of the nucleic acid comprising nanoparticles. Furthermore, the present invention is directed to medical or diagnostic devices, particularly stents and implants coated by a (biodegradable) polymer with the nucleic acid comprising nanoparticles for reversible immobilization and/or controlled release. Furthermore, the present invention is directed to the use of these nanoparticles coated with a (biodegradable) polymer and to the use of medical devices and implants coated by the (biodegradable) polymer with these nucleic acid comprising nanoparticles in the prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of restenosis, calicification, foreign body reaction, or inflammation. Additionally, the present invention is directed to a method of preparing these nucleic acid comprising nanoparticles coated with a (biodegradable) polymer and to a method for coating nucleic acid comprising nanoparticles by a (biodegradable) polymer on medical or diagnostic devices. | ||||||
| 11 | Process for production of recombinant proteins as a soluble form | US14476624 | 2014-09-03 | US09738692B2 | 2017-08-22 | Satoshi Inouye; Yuiko Sahara |
| A target protein is prepared as soluble protein using a recombinant protein expression system. An expression vector is used that includes (1) an expression-inducible promoter sequence; (2) a first coding sequence including a polynucleotide coding for a polypeptide that is represented by the formula (Z)n; and (3) a second coding sequence that includes a polynucleotide that codes for a target protein. A method of producing the target protein is also used that includes expressing protein using this expression vector. | ||||||
| 12 | PARAMYXOVIRUS VIRUS-LIKE PARTICLES AS PROTEIN DELIVERY VEHICLES | US15383324 | 2016-12-19 | US20170175086A1 | 2017-06-22 | Anthony Paul Schmitt; Phuong Tieu Schmitt; Greeshma Vivekananda Ray |
| Provided are modified virus-like particles (VLPs) of paramyxoviruses, compositions containing them, methods of using the VLPs for delivery of any particular protein of interest to any of a variety of cells, kits that contain expression vectors for making, using and detecting VLPs, and methods for screening for anti-viral compounds using the VLPs. The modified VLPs contain a contiguous recombinant polypeptide that contains i) all or a segment of a C-terminal domain of a paramyxovirus nucleocapsid protein and ii) a polypeptide sequence of a distinct protein. Non-covalent complexes of paramyxovirus M protein and fusion proteins that contain a C-terminal domain of a paramyxovirus nucleocapsid protein and a polypeptide sequence of a distinct protein are provided, as are non-covalent complexes of cells, and cell receptors, with modified VLPs. | ||||||
| 13 | Mutated genes for the catalytic protein of oplophorus luciferase and use thereof | US14576366 | 2014-12-19 | US09382520B2 | 2016-07-05 | Satoshi Inouye; Junichi Sato |
| Secreted luciferases which are different from those known heretofore have been desired. The present invention provides a luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from amino acids at the positions of 1 to 4 is deleted in the amino acid sequence of SEQ ID NO: 2. | ||||||
| 14 | REVERSIBLE IMMOBILIZATION AND/OR CONTROLLED RELEASE OF NUCLEIC ACID CONTAINING NANOPARTICLES BY (BIODEGRADABLE) POLYMER COATINGS | US14402053 | 2012-05-25 | US20150306249A1 | 2015-10-29 | Patrick BAUMHOF; Hans-Peter WENDEL; Andrea NOLTE; Tobias WALKER |
| The present invention relates to nanoparticles comprising nucleic acids coated with a (biodegradable) polymer for reversible immobilization and/or controlled release of the nucleic acid comprising nanoparticles. Furthermore, the present invention is directed to medical or diagnostic devices, particularly stents and implants coated by a (biodegradable) polymer with the nucleic acid comprising nanoparticles for reversible immobilization and/or controlled release. Furthermore, the present invention is directed to the use of these nanoparticles coated with a (biodegradable) polymer and to the use of medical devices and implants coated by the (biodegradable) polymer with these nucleic acid comprising nanoparticles in the prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of restenosis, calicification, foreign body reaction, or inflammation. Additionally, the present invention is directed to a method of preparing these nucleic acid comprising nanoparticles coated with a (biodegradable) polymer and to a method for coating nucleic acid comprising nanoparticles by a (biodegradable) polymer on medical or diagnostic devices. | ||||||
| 15 | Gaussia luciferase variant for high-throughput screening | US13381788 | 2010-06-30 | US08980603B2 | 2015-03-17 | Bakhos A. Tannous; Casey Maguire |
| Described herein is a variant of wild type Gaussia luciferase that catalyzes glow-type emission kinetics suited for high-throughput functional screening applications. Polypeptides, functional fragments, variants, and nucleic acids that encode the enhanced luciferase are further described. One such polypeptide corresponds to wild type Gaussia luciferase with a substitution mutation of I for M at position 43 of the mature peptide. Methods of use, assay systems and kits that contain the polypeptides and/or nucleic acids are further described. | ||||||
| 16 | RET2IR CONJUGATES, RET2IR CONJUGATE SYSTEMS AND METHODS OF USE THEREOF | US13802999 | 2013-03-14 | US20130272966A1 | 2013-10-17 | Liqin Xiong; Jianghong Rao |
| Embodiments of the present disclosure include conjugate systems, methods of using conjugate systems, RET2IR conjugates (also referred to as “BRET-FRET-NIR conjugates”), systems including RET2IR conjugates, methods of using the RET2IR conjugates, and the like. In general, embodiments of the present disclosure involve the non-radiative transfer of energy between a bioluminescence donor molecule and a semiconductor polymer and then the non-radiative transfer of energy between the semiconductor polymer and an NIR dye, all without external illumination. | ||||||
| 17 | METHOD OF IMMOBILIZING A PROTEIN OR MOLECULE VIA A MUTANT DEHALOGENASE THAT IS BOUND TO AN IMMOBILIZED DEHALOGENASE SUBSTRATE AND LINKED DIRECTLY OR INDIRECTLY TO THE PROTEIN OR MOLECULE | US13021295 | 2011-02-04 | US20110207195A1 | 2011-08-25 | Aldis Darzins; Lance Encell; Tonny Johnson; Dieter Klaubert; Georgyi V. Los; Mark McDougall; Keith V. Wood; Monika G. Wood; Chad Zimprich |
| A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate and has at least two amino acid substitutions relative to the wild-type hydrolase. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein. | ||||||
| 18 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | US11006031 | 2004-12-06 | US07429472B2 | 2008-09-30 | Aldis Darzins; Lance Encell; Dieter Klaubert; Georgyi V. Los; Mark McDougall; Keith V. Wood; Monika G. Wood; Chad Zimprich |
| A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate and has at least two amino acid substitutions relative to the wild-type hydrolase. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein. | ||||||
| 19 | A METHOD OF DELAYING THE ONSET OF DIABETES | US10257221 | 2001-04-17 | US20050187173A1 | 2005-08-25 | Alan Escher; Jingxue Liu |
| A method for preventing, delaying the onset of or treating diabetes in a patient comprising selecting a patient who is susceptible to developing diabetes, who is developing diabetes or who is diabetic and administering to the patient one or more than one dose of a pharmaceutical agent comprising a polynucleotide encoding a secreted exogenous protein, such as a secreted luciferase or a secreted form of human glutamic acid decarboxylase. | ||||||
| 20 | 新規セレンテラジン基質及び使用法 | JP2018040100 | 2018-03-06 | JP2018127459A | 2018-08-16 | クラウバート ディーター エイチ; マイゼンハイマー ポンチョ; アンク ジェームズ |
| 【課題】新規セレンテラジン基質及び使用法を提供する。 【解決手段】改変されたルシフェラーゼポリペプチドおよび新規のセレンテラジンベースの基質をコードする単離ポリヌクレオチド。OgLuc変異体ポリペプチドは、配列番号1に対し少なくとも60%のアミノ酸配列同一性、および配列番号1中のアミノ酸に対応する位置に少なくとも1つのアミノ酸置換を有する。OgLuc変異体ポリペプチドは、野生型オキヒオドシエビ属(Oplophorus)ルシフェラーゼの対応するポリペプチドと比較して、増強された発光、増強されたシグナル安定性、および増強されたタンパク質安定性のうち少なくとも1つを有する。 【選択図】なし |
||||||
QQ群二维码
意见反馈
意见反馈